Baotou Dongbao Bio-TechLtd（300239）株式概要包頭東宝生物科技有限公司は、中華人民共和国および国際的に、ゼラチン、コラーゲンおよびその他の製品の研究開発、製造、販売を行っている。 詳細300239 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績1/6財務の健全性5/6配当金1/6リスク分析財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見る300239 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW468,992 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA468,992 investors already sharing narrativesYour Fair ValueCN¥Current PriceCN¥4.9831.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0988m2016201920222025202620282031Revenue CN¥916.0mEarnings CN¥63.4mAdvancedSet Fair ValueView all narrativesBaotou Dongbao Bio-Tech Co.,Ltd 競合他社Luoyang Jianlong Micro-nano New MaterialSymbol: SHSE:688357Market cap: CN¥2.7bQingdao Copton TechnologySymbol: SHSE:603798Market cap: CN¥3.2bHangzhou FlariantLtdSymbol: SHSE:605566Market cap: CN¥3.3bJiangxi Selon IndustrialSymbol: SZSE:002748Market cap: CN¥2.9b価格と性能株価の高値、安値、推移の概要Baotou Dongbao Bio-TechLtd過去の株価現在の株価CN¥4.9852週高値CN¥6.8252週安値CN¥4.46ベータ0.181ヶ月の変化10.18%3ヶ月変化-2.16%1年変化-16.58%3年間の変化-20.45%5年間の変化-20.95%IPOからの変化-3.73%最新ニュースReported Earnings • 1hSecond quarter 2026 earnings released: EPS: CN¥0.03 (vs CN¥0.031 in 2Q 2025)Second quarter 2026 results: EPS: CN¥0.03 (down from CN¥0.031 in 2Q 2025). Revenue: CN¥224.2m (up 24% from 2Q 2025). Net income: CN¥17.7m (down 1.2% from 2Q 2025). Profit margin: 7.9% (down from 9.9% in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Jun 30Baotou Dongbao Bio-Tech Co.,Ltd to Report First Half, 2026 Results on Aug 24, 2026Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report first half, 2026 results on Aug 24, 2026Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥5.47, the stock trades at a trailing P/E ratio of 58x. Average trailing P/E is 49x in the Chemicals industry in China. Total loss to shareholders of 7.7% over the past three years.お知らせ • Mar 31Baotou Dongbao Bio-Tech Co.,Ltd to Report Q1, 2026 Results on Apr 24, 2026Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q1, 2026 results on Apr 24, 2026New Risk • Mar 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.Reported Earnings • Mar 30Full year 2025 earnings released: EPS: CN¥0.093 (vs CN¥0.14 in FY 2024)Full year 2025 results: EPS: CN¥0.093 (down from CN¥0.14 in FY 2024). Revenue: CN¥745.3m (down 16% from FY 2024). Net income: CN¥54.3m (down 37% from FY 2024). Profit margin: 7.3% (down from 9.7% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.最新情報をもっと見るRecent updatesReported Earnings • 1hSecond quarter 2026 earnings released: EPS: CN¥0.03 (vs CN¥0.031 in 2Q 2025)Second quarter 2026 results: EPS: CN¥0.03 (down from CN¥0.031 in 2Q 2025). Revenue: CN¥224.2m (up 24% from 2Q 2025). Net income: CN¥17.7m (down 1.2% from 2Q 2025). Profit margin: 7.9% (down from 9.9% in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Jun 30Baotou Dongbao Bio-Tech Co.,Ltd to Report First Half, 2026 Results on Aug 24, 2026Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report first half, 2026 results on Aug 24, 2026Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥5.47, the stock trades at a trailing P/E ratio of 58x. Average trailing P/E is 49x in the Chemicals industry in China. Total loss to shareholders of 7.7% over the past three years.お知らせ • Mar 31Baotou Dongbao Bio-Tech Co.,Ltd to Report Q1, 2026 Results on Apr 24, 2026Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q1, 2026 results on Apr 24, 2026New Risk • Mar 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.Reported Earnings • Mar 30Full year 2025 earnings released: EPS: CN¥0.093 (vs CN¥0.14 in FY 2024)Full year 2025 results: EPS: CN¥0.093 (down from CN¥0.14 in FY 2024). Revenue: CN¥745.3m (down 16% from FY 2024). Net income: CN¥54.3m (down 37% from FY 2024). Profit margin: 7.3% (down from 9.7% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • Mar 29Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, Apr 28, 2026Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, Apr 28, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Baotou, Inner Mongolia Chinaお知らせ • Dec 31Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2025 Results on Mar 30, 2026Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2025 results on Mar 30, 2026Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: CN¥0.02 (vs CN¥0.025 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.02 (down from CN¥0.025 in 3Q 2024). Revenue: CN¥163.7m (down 13% from 3Q 2024). Net income: CN¥11.5m (down 23% from 3Q 2024). Profit margin: 7.0% (down from 7.9% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year whereas the company’s share price has fallen by 12% per year.お知らせ • Sep 30Baotou Dongbao Bio-Tech Co.,Ltd to Report Q3, 2025 Results on Oct 29, 2025Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q3, 2025 results on Oct 29, 2025New Risk • Aug 29New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Board Change • Jul 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jing Wang was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 02Baotou Dongbao Bio-Tech Co.,Ltd to Report First Half, 2025 Results on Aug 29, 2025Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • Apr 25Baotou Dongbao Bio-Tech Co.,Ltd Proposes Final Cash Dividend for 2024Baotou Dongbao Bio-Tech Co.,Ltd announced on 24 April 2025 the profit distribution proposal for 2024 as follows: Cash dividend/10 shares (tax included): CNY 0.250.Reported Earnings • Apr 24First quarter 2025 earnings released: EPS: CN¥0.032 (vs CN¥0.044 in 1Q 2024)First quarter 2025 results: EPS: CN¥0.032 (down from CN¥0.044 in 1Q 2024). Revenue: CN¥188.0m (down 22% from 1Q 2024). Net income: CN¥19.0m (down 27% from 1Q 2024). Profit margin: 10% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Apr 24Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 15, 2025Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 15, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Baotou, Inner Mongolia Chinaお知らせ • Mar 31Baotou Dongbao Bio-Tech Co.,Ltd to Report Q1, 2025 Results on Apr 24, 2025Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q1, 2025 results on Apr 24, 2025お知らせ • Jan 07Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) announces an Equity Buyback for CNY 100 million worth of its shares.Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be repurchased at no more than CNY 8 per share. The purpose of the program is to use the repurchased shares for equity incentives or employee stock ownership plans. If the Company fails to use up all repurchased shares within three years after the announcement of the implementation results of this share repurchase and the share change, the unused repurchased shares will be cancelled according to relevant procedures. The program will be funded from the Company’s own funds and/or self-raised funds. The program is subject to approval from shareholders. The program will be valid for 12 months.お知らせ • Dec 31Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2024 Results on Apr 24, 2025Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2024 results on Apr 24, 2025Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥6.10, the stock trades at a trailing P/E ratio of 39.8x. Average trailing P/E is 36x in the Chemicals industry in China. Total loss to shareholders of 13% over the past three years.Reported Earnings • Oct 28Third quarter 2024 earnings released: EPS: CN¥0.025 (vs CN¥0.051 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.025 (down from CN¥0.051 in 3Q 2023). Revenue: CN¥188.8m (down 12% from 3Q 2023). Net income: CN¥14.9m (down 51% from 3Q 2023). Profit margin: 7.9% (down from 14% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.分析記事 • Oct 08Market Might Still Lack Some Conviction On Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) Even After 37% Share Price BoostBaotou Dongbao Bio-Tech Co.,Ltd ( SZSE:300239 ) shareholders have had their patience rewarded with a 37% share price...分析記事 • Oct 01We Like These Underlying Return On Capital Trends At Baotou Dongbao Bio-TechLtd (SZSE:300239)Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...お知らせ • Sep 30Baotou Dongbao Bio-Tech Co.,Ltd to Report Q3, 2024 Results on Oct 28, 2024Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q3, 2024 results on Oct 28, 2024Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CN¥5.58, the stock trades at a trailing P/E ratio of 31.2x. Average trailing P/E is 30x in the Chemicals industry in China. Total loss to shareholders of 12% over the past three years.Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.057 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.057 in 2Q 2023). Revenue: CN¥202.5m (down 22% from 2Q 2023). Net income: CN¥25.4m (down 25% from 2Q 2023). Profit margin: 13% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.New Risk • Jul 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Jun 29Baotou Dongbao Bio-Tech Co.,Ltd to Report First Half, 2024 Results on Aug 28, 2024Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report first half, 2024 results on Aug 28, 2024Board Change • Jun 01High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 2 experienced directors. 3 highly experienced directors. GM & Director Fang Liu is the most experienced director on the board, commencing their role in 2000. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.分析記事 • May 27Baotou Dongbao Bio-TechLtd's (SZSE:300239) Dividend Will Be Reduced To CN¥0.022Baotou Dongbao Bio-Tech Co.,Ltd ( SZSE:300239 ) has announced that on 31st of May, it will be paying a dividend...Declared Dividend • May 27Dividend reduced to CN¥0.022Dividend of CN¥0.022 is 15% lower than last year. Ex-date: 31st May 2024 Payment date: 31st May 2024 Dividend yield will be 0.4%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (11% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 21% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • May 25Baotou Dongbao Bio-Tech Co.,Ltd Announced 2023 Final Cash Distribution Plan on A Shares, Payable on 31 May 2024Baotou Dongbao Bio-Tech Co.,Ltd announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included) of CNY 0.22000000. Record date: 30 May 2024. Ex-date: 31 May 2024. Payment date: 31 May 2024.Valuation Update With 7 Day Price Move • May 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥6.25, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 35x in the Chemicals industry in China. Total loss to shareholders of 14% over the past three years.お知らせ • Apr 24Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 14, 2024Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 14, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Baotou, Inner Mongolia ChinaReported Earnings • Apr 24First quarter 2024 earnings released: EPS: CN¥0.044 (vs CN¥0.053 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.044 (down from CN¥0.053 in 1Q 2023). Revenue: CN¥241.8m (down 7.5% from 1Q 2023). Net income: CN¥26.0m (down 17% from 1Q 2023). Profit margin: 11% (down from 12% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Apr 08Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 17% to CN¥5.07. The fair value is estimated to be CN¥6.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%.お知らせ • Mar 30Baotou Dongbao Bio-Tech Co.,Ltd to Report Q1, 2024 Results on Apr 26, 2024Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q1, 2024 results on Apr 26, 2024Buy Or Sell Opportunity • Mar 22Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to CN¥5.10. The fair value is estimated to be CN¥6.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%.Buy Or Sell Opportunity • Mar 05Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to CN¥5.10. The fair value is estimated to be CN¥6.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%.New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Feb 28Investor sentiment improves as stock rises 33%After last week's 33% share price gain to CN¥6.01, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 29x in the Chemicals industry in China. Total returns to shareholders of 9.0% over the past three years.分析記事 • Feb 28Sentiment Still Eluding Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239)With a price-to-earnings (or "P/E") ratio of 25.4x Baotou Dongbao Bio-Tech Co.,Ltd ( SZSE:300239 ) may be sending...Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CN¥4.44, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 28x in the Chemicals industry in China. Total loss to shareholders of 14% over the past three years.Buy Or Sell Opportunity • Feb 01Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 26% to CN¥4.76. The fair value is estimated to be CN¥5.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%.お知らせ • Dec 30Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2023 results on Apr 26, 2024Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.051 (vs CN¥0.05 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.051 (up from CN¥0.05 in 3Q 2022). Revenue: CN¥214.0m (down 6.8% from 3Q 2022). Net income: CN¥30.3m (up 1.5% from 3Q 2022). Profit margin: 14% (up from 13% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Oct 01Baotou Dongbao Bio-Tech Co.,Ltd to Report Q3, 2023 Results on Oct 30, 2023Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q3, 2023 results on Oct 30, 2023Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.057 (vs CN¥0.058 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.057 (down from CN¥0.058 in 2Q 2022). Revenue: CN¥259.4m (up 4.5% from 2Q 2022). Net income: CN¥33.9m (down 1.1% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • May 12Baotou Dongbao Bio-Tech Co.,Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 19 May 2023Baotou Dongbao Bio-Tech Co.,Ltd announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 0.26000000. Record date: 18 May 2023, Ex-date: 19 May 2023, Payment date: 19 May 2023.Reported Earnings • Mar 22Full year 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.065 in FY 2021)Full year 2022 results: EPS: CN¥0.18 (up from CN¥0.065 in FY 2021). Revenue: CN¥943.4m (up 54% from FY 2021). Net income: CN¥109.4m (up 200% from FY 2021). Profit margin: 12% (up from 6.0% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Deputy GM & Director Furong Wang is the most experienced director on the board, commencing their role in 2017. Independent Director Tao Ketao Erdun was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.01 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.05 (up from CN¥0.01 in 3Q 2021). Revenue: CN¥229.7m (up 69% from 3Q 2021). Net income: CN¥29.8m (up 381% from 3Q 2021). Profit margin: 13% (up from 4.6% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 29Second quarter 2022 earnings released: EPS: CN¥0.058 (vs CN¥0.005 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.058 (up from CN¥0.005 in 2Q 2021). Revenue: CN¥248.2m (up 79% from 2Q 2021). Net income: CN¥34.3m (up CN¥31.3m from 2Q 2021). Profit margin: 14% (up from 2.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jun 03Baotou Dongbao Bio-Tech Co.,Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 10 June 2022Baotou Dongbao Bio-Tech Co.,Ltd announced 2021 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 0.06000000. Record date: 09 June 2022, Ex-date: 10 June 2022, Payment date: 10 June 2022. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY0.00600000(10% x CNY0.06000000) Net cash dividend/10 shares after tax: CNY0.05400000(CNY0.06000000- CNY0.00600000).お知らせ • May 20Baotou Dongbao Bio-Tech Co.,Ltd Approves Profit Distribution Plan for 2021Baotou Dongbao Bio-Tech Co.,Ltd announced that at the Annual General Meeting held on 18 May 2022, approved cash dividend (tax included) of CNY 0.06000000 per ten shares for 2021.Valuation Update With 7 Day Price Move • May 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥7.03, the stock trades at a trailing P/E ratio of 75.1x. Average trailing P/E is 23x in the Chemicals industry in China. Total returns to shareholders of 56% over the past three years.お知らせ • Apr 27Baotou Dongbao Bio-Tech Co.,Ltd Proposes Cash Dividend for 2021Baotou Dongbao Bio-Tech Co.,Ltd proposed cash dividend of CNY 0.06000000 (tax included) per 10 shares for 2021.Board Change • Apr 27High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Supervisor Tingting Yang is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Nov 01High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Supervisor Tingting Yang is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.01 (vs CN¥0.007 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥135.6m (up 19% from 3Q 2020). Net income: CN¥6.19m (up 64% from 3Q 2020). Profit margin: 4.6% (up from 3.3% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.Board Change • Oct 02High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Supervisor Tingting Yang is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 26Second quarter 2021 earnings released: EPS CN¥0.005 (vs CN¥0.006 in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥138.5m (up 43% from 2Q 2020). Net income: CN¥2.92m (down 11% from 2Q 2020). Profit margin: 2.1% (down from 3.4% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.Reported Earnings • Apr 16Full year 2020 earnings released: EPS CN¥0.035 (vs CN¥0.07 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥448.8m (down 8.7% from FY 2019). Net income: CN¥18.5m (down 48% from FY 2019). Profit margin: 4.1% (down from 7.2% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Mar 09Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2020 Results on Apr 23, 2021Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2020 results on Apr 23, 2021Is New 90 Day High Low • Jan 29New 90-day low: CN¥4.84The company is down 27% from its price of CN¥6.64 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.Is New 90 Day High Low • Jan 11New 90-day low: CN¥5.13The company is down 30% from its price of CN¥7.38 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.Is New 90 Day High Low • Dec 15New 90-day high: CN¥7.56The company is up 3.0% from its price of CN¥7.34 on 15 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 6.0% over the same period.Is New 90 Day High Low • Nov 26New 90-day low: CN¥5.83The company is down 4.0% from its price of CN¥6.06 on 28 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥22.3m, down 37% from the prior year. Total revenue was CN¥453.8m over the last 12 months, down 3.4% from the prior year.お知らせ • Jul 23Baotou Dongbao Bio-Tech Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020Baotou Dongbao Bio-Tech Co., Ltd. announced that they will report first half, 2020 results on Aug 18, 2020株主還元300239CN ChemicalsCN 市場7D-2.9%-0.8%-1.5%1Y-16.6%22.2%3.9%株主還元を見る業界別リターン: 300239過去 1 年間で22.2 % の収益を上げたCN Chemicals業界を下回りました。リターン対市場: 300239は、過去 1 年間で3.9 % のリターンを上げたCN市場を下回りました。価格変動Is 300239's price volatile compared to industry and market?300239 volatility300239 Average Weekly Movement6.1%Chemicals Industry Average Movement7.7%Market Average Movement7.4%10% most volatile stocks in CN Market12.6%10% least volatile stocks in CN Market4.4%安定した株価: 300239 、 CN市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 300239の 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19601,424Fang Liuwww.dongbaoshengwu.com包頭東宝生物科技有限公司は、中華人民共和国および国際的に、ゼラチン、コラーゲンおよびその他の製品の研究開発、製造、販売を行っている。ゼリー、菓子、ヨーグルト、代用血漿、錠剤、ソフトジェル、印画紙、ハードカプセル用ゼラチン、代用血漿ゼラチン、中空カプセル、二重タンパク質食物繊維、化粧品などの製品、凝集コラーゲンペプチド、加水分解コラーゲンパワーと顆粒、コラーゲンペプチドパワーと顆粒、加水分解フィッシュコラーゲン、コラーゲンジャー、フィッシュコラーゲンペプチドパウダー、食品添加物、医薬用ゼラチンを提供している。また、工業用・飼料用リン酸水素カルシウム、無機・有機微生物肥料、窒素肥料、アミノ酸カルシウム肥料、骨由来生物カルシウム肥料、生物・精製有機肥料などの生物有機肥料の研究開発・製造・販売も行っている。また、空カプセルの研究開発、製造、販売も行っている。同社は1960年に設立され、中華人民共和国の包頭市に本社を置いている。もっと見るBaotou Dongbao Bio-Tech Co.,Ltd 基礎のまとめBaotou Dongbao Bio-TechLtd の収益と売上を時価総額と比較するとどうか。300239 基礎統計学時価総額CN¥2.90b収益（TTM）CN¥54.77m売上高(TTM)CN¥790.94m53.0xPER（株価収益率3.7xP/Sレシオ300239 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計300239 損益計算書（TTM）収益CN¥790.94m売上原価CN¥635.31m売上総利益CN¥155.64mその他の費用CN¥100.86m収益CN¥54.77m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）0.094グロス・マージン19.68%純利益率6.93%有利子負債／自己資本比率29.0%300239 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.2%現在の配当利回り13%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/24 18:31終値2026/08/24 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Baotou Dongbao Bio-Tech Co.,Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jie YaoEverbright Securities Co. Ltd.
Reported Earnings • 1hSecond quarter 2026 earnings released: EPS: CN¥0.03 (vs CN¥0.031 in 2Q 2025)Second quarter 2026 results: EPS: CN¥0.03 (down from CN¥0.031 in 2Q 2025). Revenue: CN¥224.2m (up 24% from 2Q 2025). Net income: CN¥17.7m (down 1.2% from 2Q 2025). Profit margin: 7.9% (down from 9.9% in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 30Baotou Dongbao Bio-Tech Co.,Ltd to Report First Half, 2026 Results on Aug 24, 2026Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report first half, 2026 results on Aug 24, 2026
Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥5.47, the stock trades at a trailing P/E ratio of 58x. Average trailing P/E is 49x in the Chemicals industry in China. Total loss to shareholders of 7.7% over the past three years.
お知らせ • Mar 31Baotou Dongbao Bio-Tech Co.,Ltd to Report Q1, 2026 Results on Apr 24, 2026Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q1, 2026 results on Apr 24, 2026
New Risk • Mar 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
Reported Earnings • Mar 30Full year 2025 earnings released: EPS: CN¥0.093 (vs CN¥0.14 in FY 2024)Full year 2025 results: EPS: CN¥0.093 (down from CN¥0.14 in FY 2024). Revenue: CN¥745.3m (down 16% from FY 2024). Net income: CN¥54.3m (down 37% from FY 2024). Profit margin: 7.3% (down from 9.7% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Reported Earnings • 1hSecond quarter 2026 earnings released: EPS: CN¥0.03 (vs CN¥0.031 in 2Q 2025)Second quarter 2026 results: EPS: CN¥0.03 (down from CN¥0.031 in 2Q 2025). Revenue: CN¥224.2m (up 24% from 2Q 2025). Net income: CN¥17.7m (down 1.2% from 2Q 2025). Profit margin: 7.9% (down from 9.9% in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 30Baotou Dongbao Bio-Tech Co.,Ltd to Report First Half, 2026 Results on Aug 24, 2026Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report first half, 2026 results on Aug 24, 2026
Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥5.47, the stock trades at a trailing P/E ratio of 58x. Average trailing P/E is 49x in the Chemicals industry in China. Total loss to shareholders of 7.7% over the past three years.
お知らせ • Mar 31Baotou Dongbao Bio-Tech Co.,Ltd to Report Q1, 2026 Results on Apr 24, 2026Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q1, 2026 results on Apr 24, 2026
New Risk • Mar 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
Reported Earnings • Mar 30Full year 2025 earnings released: EPS: CN¥0.093 (vs CN¥0.14 in FY 2024)Full year 2025 results: EPS: CN¥0.093 (down from CN¥0.14 in FY 2024). Revenue: CN¥745.3m (down 16% from FY 2024). Net income: CN¥54.3m (down 37% from FY 2024). Profit margin: 7.3% (down from 9.7% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 29Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, Apr 28, 2026Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, Apr 28, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Baotou, Inner Mongolia China
お知らせ • Dec 31Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2025 Results on Mar 30, 2026Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2025 results on Mar 30, 2026
Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: CN¥0.02 (vs CN¥0.025 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.02 (down from CN¥0.025 in 3Q 2024). Revenue: CN¥163.7m (down 13% from 3Q 2024). Net income: CN¥11.5m (down 23% from 3Q 2024). Profit margin: 7.0% (down from 7.9% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year whereas the company’s share price has fallen by 12% per year.
お知らせ • Sep 30Baotou Dongbao Bio-Tech Co.,Ltd to Report Q3, 2025 Results on Oct 29, 2025Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q3, 2025 results on Oct 29, 2025
New Risk • Aug 29New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Board Change • Jul 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jing Wang was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 02Baotou Dongbao Bio-Tech Co.,Ltd to Report First Half, 2025 Results on Aug 29, 2025Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Apr 25Baotou Dongbao Bio-Tech Co.,Ltd Proposes Final Cash Dividend for 2024Baotou Dongbao Bio-Tech Co.,Ltd announced on 24 April 2025 the profit distribution proposal for 2024 as follows: Cash dividend/10 shares (tax included): CNY 0.250.
Reported Earnings • Apr 24First quarter 2025 earnings released: EPS: CN¥0.032 (vs CN¥0.044 in 1Q 2024)First quarter 2025 results: EPS: CN¥0.032 (down from CN¥0.044 in 1Q 2024). Revenue: CN¥188.0m (down 22% from 1Q 2024). Net income: CN¥19.0m (down 27% from 1Q 2024). Profit margin: 10% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Apr 24Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 15, 2025Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 15, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Baotou, Inner Mongolia China
お知らせ • Mar 31Baotou Dongbao Bio-Tech Co.,Ltd to Report Q1, 2025 Results on Apr 24, 2025Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q1, 2025 results on Apr 24, 2025
お知らせ • Jan 07Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) announces an Equity Buyback for CNY 100 million worth of its shares.Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be repurchased at no more than CNY 8 per share. The purpose of the program is to use the repurchased shares for equity incentives or employee stock ownership plans. If the Company fails to use up all repurchased shares within three years after the announcement of the implementation results of this share repurchase and the share change, the unused repurchased shares will be cancelled according to relevant procedures. The program will be funded from the Company’s own funds and/or self-raised funds. The program is subject to approval from shareholders. The program will be valid for 12 months.
お知らせ • Dec 31Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2024 Results on Apr 24, 2025Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2024 results on Apr 24, 2025
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥6.10, the stock trades at a trailing P/E ratio of 39.8x. Average trailing P/E is 36x in the Chemicals industry in China. Total loss to shareholders of 13% over the past three years.
Reported Earnings • Oct 28Third quarter 2024 earnings released: EPS: CN¥0.025 (vs CN¥0.051 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.025 (down from CN¥0.051 in 3Q 2023). Revenue: CN¥188.8m (down 12% from 3Q 2023). Net income: CN¥14.9m (down 51% from 3Q 2023). Profit margin: 7.9% (down from 14% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
分析記事 • Oct 08Market Might Still Lack Some Conviction On Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) Even After 37% Share Price BoostBaotou Dongbao Bio-Tech Co.,Ltd ( SZSE:300239 ) shareholders have had their patience rewarded with a 37% share price...
分析記事 • Oct 01We Like These Underlying Return On Capital Trends At Baotou Dongbao Bio-TechLtd (SZSE:300239)Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...
お知らせ • Sep 30Baotou Dongbao Bio-Tech Co.,Ltd to Report Q3, 2024 Results on Oct 28, 2024Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q3, 2024 results on Oct 28, 2024
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CN¥5.58, the stock trades at a trailing P/E ratio of 31.2x. Average trailing P/E is 30x in the Chemicals industry in China. Total loss to shareholders of 12% over the past three years.
Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.057 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.057 in 2Q 2023). Revenue: CN¥202.5m (down 22% from 2Q 2023). Net income: CN¥25.4m (down 25% from 2Q 2023). Profit margin: 13% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
New Risk • Jul 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Jun 29Baotou Dongbao Bio-Tech Co.,Ltd to Report First Half, 2024 Results on Aug 28, 2024Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report first half, 2024 results on Aug 28, 2024
Board Change • Jun 01High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 2 experienced directors. 3 highly experienced directors. GM & Director Fang Liu is the most experienced director on the board, commencing their role in 2000. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
分析記事 • May 27Baotou Dongbao Bio-TechLtd's (SZSE:300239) Dividend Will Be Reduced To CN¥0.022Baotou Dongbao Bio-Tech Co.,Ltd ( SZSE:300239 ) has announced that on 31st of May, it will be paying a dividend...
Declared Dividend • May 27Dividend reduced to CN¥0.022Dividend of CN¥0.022 is 15% lower than last year. Ex-date: 31st May 2024 Payment date: 31st May 2024 Dividend yield will be 0.4%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (11% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 21% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • May 25Baotou Dongbao Bio-Tech Co.,Ltd Announced 2023 Final Cash Distribution Plan on A Shares, Payable on 31 May 2024Baotou Dongbao Bio-Tech Co.,Ltd announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included) of CNY 0.22000000. Record date: 30 May 2024. Ex-date: 31 May 2024. Payment date: 31 May 2024.
Valuation Update With 7 Day Price Move • May 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥6.25, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 35x in the Chemicals industry in China. Total loss to shareholders of 14% over the past three years.
お知らせ • Apr 24Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 14, 2024Baotou Dongbao Bio-Tech Co.,Ltd, Annual General Meeting, May 14, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Baotou, Inner Mongolia China
Reported Earnings • Apr 24First quarter 2024 earnings released: EPS: CN¥0.044 (vs CN¥0.053 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.044 (down from CN¥0.053 in 1Q 2023). Revenue: CN¥241.8m (down 7.5% from 1Q 2023). Net income: CN¥26.0m (down 17% from 1Q 2023). Profit margin: 11% (down from 12% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Apr 08Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 17% to CN¥5.07. The fair value is estimated to be CN¥6.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%.
お知らせ • Mar 30Baotou Dongbao Bio-Tech Co.,Ltd to Report Q1, 2024 Results on Apr 26, 2024Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q1, 2024 results on Apr 26, 2024
Buy Or Sell Opportunity • Mar 22Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to CN¥5.10. The fair value is estimated to be CN¥6.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%.
Buy Or Sell Opportunity • Mar 05Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to CN¥5.10. The fair value is estimated to be CN¥6.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%.
New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Feb 28Investor sentiment improves as stock rises 33%After last week's 33% share price gain to CN¥6.01, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 29x in the Chemicals industry in China. Total returns to shareholders of 9.0% over the past three years.
分析記事 • Feb 28Sentiment Still Eluding Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239)With a price-to-earnings (or "P/E") ratio of 25.4x Baotou Dongbao Bio-Tech Co.,Ltd ( SZSE:300239 ) may be sending...
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CN¥4.44, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 28x in the Chemicals industry in China. Total loss to shareholders of 14% over the past three years.
Buy Or Sell Opportunity • Feb 01Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 26% to CN¥4.76. The fair value is estimated to be CN¥5.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 63%.
お知らせ • Dec 30Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2023 results on Apr 26, 2024
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.051 (vs CN¥0.05 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.051 (up from CN¥0.05 in 3Q 2022). Revenue: CN¥214.0m (down 6.8% from 3Q 2022). Net income: CN¥30.3m (up 1.5% from 3Q 2022). Profit margin: 14% (up from 13% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Oct 01Baotou Dongbao Bio-Tech Co.,Ltd to Report Q3, 2023 Results on Oct 30, 2023Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report Q3, 2023 results on Oct 30, 2023
Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.057 (vs CN¥0.058 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.057 (down from CN¥0.058 in 2Q 2022). Revenue: CN¥259.4m (up 4.5% from 2Q 2022). Net income: CN¥33.9m (down 1.1% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • May 12Baotou Dongbao Bio-Tech Co.,Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 19 May 2023Baotou Dongbao Bio-Tech Co.,Ltd announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 0.26000000. Record date: 18 May 2023, Ex-date: 19 May 2023, Payment date: 19 May 2023.
Reported Earnings • Mar 22Full year 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.065 in FY 2021)Full year 2022 results: EPS: CN¥0.18 (up from CN¥0.065 in FY 2021). Revenue: CN¥943.4m (up 54% from FY 2021). Net income: CN¥109.4m (up 200% from FY 2021). Profit margin: 12% (up from 6.0% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Deputy GM & Director Furong Wang is the most experienced director on the board, commencing their role in 2017. Independent Director Tao Ketao Erdun was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.01 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.05 (up from CN¥0.01 in 3Q 2021). Revenue: CN¥229.7m (up 69% from 3Q 2021). Net income: CN¥29.8m (up 381% from 3Q 2021). Profit margin: 13% (up from 4.6% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 29Second quarter 2022 earnings released: EPS: CN¥0.058 (vs CN¥0.005 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.058 (up from CN¥0.005 in 2Q 2021). Revenue: CN¥248.2m (up 79% from 2Q 2021). Net income: CN¥34.3m (up CN¥31.3m from 2Q 2021). Profit margin: 14% (up from 2.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jun 03Baotou Dongbao Bio-Tech Co.,Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 10 June 2022Baotou Dongbao Bio-Tech Co.,Ltd announced 2021 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 0.06000000. Record date: 09 June 2022, Ex-date: 10 June 2022, Payment date: 10 June 2022. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY0.00600000(10% x CNY0.06000000) Net cash dividend/10 shares after tax: CNY0.05400000(CNY0.06000000- CNY0.00600000).
お知らせ • May 20Baotou Dongbao Bio-Tech Co.,Ltd Approves Profit Distribution Plan for 2021Baotou Dongbao Bio-Tech Co.,Ltd announced that at the Annual General Meeting held on 18 May 2022, approved cash dividend (tax included) of CNY 0.06000000 per ten shares for 2021.
Valuation Update With 7 Day Price Move • May 02Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥7.03, the stock trades at a trailing P/E ratio of 75.1x. Average trailing P/E is 23x in the Chemicals industry in China. Total returns to shareholders of 56% over the past three years.
お知らせ • Apr 27Baotou Dongbao Bio-Tech Co.,Ltd Proposes Cash Dividend for 2021Baotou Dongbao Bio-Tech Co.,Ltd proposed cash dividend of CNY 0.06000000 (tax included) per 10 shares for 2021.
Board Change • Apr 27High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Supervisor Tingting Yang is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Nov 01High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Supervisor Tingting Yang is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.01 (vs CN¥0.007 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥135.6m (up 19% from 3Q 2020). Net income: CN¥6.19m (up 64% from 3Q 2020). Profit margin: 4.6% (up from 3.3% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
Board Change • Oct 02High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Supervisor Tingting Yang is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 26Second quarter 2021 earnings released: EPS CN¥0.005 (vs CN¥0.006 in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥138.5m (up 43% from 2Q 2020). Net income: CN¥2.92m (down 11% from 2Q 2020). Profit margin: 2.1% (down from 3.4% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 16Full year 2020 earnings released: EPS CN¥0.035 (vs CN¥0.07 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥448.8m (down 8.7% from FY 2019). Net income: CN¥18.5m (down 48% from FY 2019). Profit margin: 4.1% (down from 7.2% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Mar 09Baotou Dongbao Bio-Tech Co.,Ltd to Report Fiscal Year 2020 Results on Apr 23, 2021Baotou Dongbao Bio-Tech Co.,Ltd announced that they will report fiscal year 2020 results on Apr 23, 2021
Is New 90 Day High Low • Jan 29New 90-day low: CN¥4.84The company is down 27% from its price of CN¥6.64 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.
Is New 90 Day High Low • Jan 11New 90-day low: CN¥5.13The company is down 30% from its price of CN¥7.38 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period.
Is New 90 Day High Low • Dec 15New 90-day high: CN¥7.56The company is up 3.0% from its price of CN¥7.34 on 15 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Nov 26New 90-day low: CN¥5.83The company is down 4.0% from its price of CN¥6.06 on 28 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥22.3m, down 37% from the prior year. Total revenue was CN¥453.8m over the last 12 months, down 3.4% from the prior year.
お知らせ • Jul 23Baotou Dongbao Bio-Tech Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020Baotou Dongbao Bio-Tech Co., Ltd. announced that they will report first half, 2020 results on Aug 18, 2020
